Clinical Trials Directory

Trials / Conditions / Human Immunodeficiency Virus (HIV)

Human Immunodeficiency Virus (HIV)

77 registered clinical trials studyying Human Immunodeficiency Virus (HIV)12 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingThe Effects of Chiropractic Care on Inflammation and Quality of Life in People Living With HIV
NCT07466836
Tyson Perez, DC, PhDN/A
Not Yet RecruitingC-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the Unite
NCT07520188
UNC Lineberger Comprehensive Cancer Center
Not Yet RecruitingHIV Testing Counselor-led Care to Catalyze Integration of PrEP Delivery in Family Planning Clinics
NCT07089966
University of WashingtonN/A
RecruitingA Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
NCT07071623
Merck Sharp & Dohme LLCPhase 3
RecruitingVoluntary HIV Screening in the General Population in France
NCT07418385
Université de Reims Champagne-Ardenne
RecruitingReducing Systemic Inflammation in People on Antiretroviral Therapy
NCT07030920
Centre hospitalier de l'Université de Montréal (CHUM)Phase 2
RecruitingQuitting Matters Human Immunodeficiency Virus Hybrid Trial
NCT06883097
Wake Forest University Health SciencesN/A
RecruitingA Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
NCT07044297
Merck Sharp & Dohme LLCPhase 3
RecruitingProject neuroARTEMIS
NCT06814275
Wake Forest University Health SciencesN/A
RecruitingThe Trans-Led Care Study
NCT06880705
Illinois Institute of TechnologyN/A
RecruitingUsing Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking C
NCT06598397
New York UniversityPhase 4
RecruitingPersuasive Health Communication Intervention for HIV/HCV
NCT05968573
University of South FloridaN/A
CompletedA Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)
NCT06783192
Merck Sharp & Dohme LLCPhase 1
Active Not RecruitingKentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk
NCT05657106
April M YoungN/A
UnknownExtraordinarily Fun Training Project in Compulsory Secondary Education - Sexually Transmitted Infections
NCT05727033
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i GurinaN/A
Completede-HERO: Ending the HIV Epidemic in Rural Oklahoma
NCT05664802
Northern Arizona UniversityN/A
CompletedSafety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adult
NCT05423418
U.S. Army Medical Research and Development CommandPhase 1
CompletedA Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet
NCT05197075
Janssen Research & Development, LLCPhase 1
CompletedStudy to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body o
NCT04554966
AbbViePhase 1
CompletedStudy to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV)
NCT04799353
AbbViePhase 1
UnknownCommunity Based Screening for HIV Self Testing in FSW in 23 Priority Districts in Indonesia
NCT04578145
Kerti Praja FoundationN/A
CompletedA Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Parti
NCT04223804
AbbViePhase 1
CompletedPOC Strategies to Improve TB Care in Advanced HIV Disease
NCT04122404
University of Southern DenmarkN/A
CompletedAlcohol Monitor Validation
NCT03617705
University of FloridaN/A
CompletedDose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy
NCT03783130
National Institute of Allergy and Infectious Diseases (NIAID)Phase 1
CompletedPharmacokinetics of Intracellular TFV-DP and FTC-TP in HIV-infected Adolescents
NCT03800394
University of Florida
CompletedMitochondria in HIV and Aging (MITO+)
NCT03489421
University of Colorado, Denver
CompletedAn Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricita
NCT03577470
Janssen-Cilag S.p.A.
CompletedSexual Hepatitis C in HIV Positive Men Who Have Sex With Men (MSM) in Bordeaux
NCT03290755
University Hospital, Bordeaux
CompletedThe Effect of Ixazomib on the Latent HIV Reservoir
NCT02946047
Mayo ClinicPhase 1 / Phase 2
TerminatedNC Young Women's CoOp
NCT02965014
RTI InternationalN/A
CompletedRomidepsin Plus 3BNC117 Phase 2a Study
NCT02850016
Rockefeller UniversityPhase 2
TerminatedAn Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study
NCT02990858
CytoDyn, Inc.Phase 2 / Phase 3
CompletedCape Town Young Women's Health CoOp
NCT02974998
RTI InternationalN/A
CompletedNew Strategies to Assess Anal Cancer Risk In Women
NCT02873741
Emory University
Completed3BNC117 and 10-1074 in HIV-infected Individuals
NCT02825797
Rockefeller UniversityPhase 1
UnknownStatus of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Vir
NCT02511496
Maimónides Biomedical Research Institute of Córdoba
CompletedTesamorelin Effects on Liver Fat and Histology in HIV
NCT02196831
Massachusetts General HospitalN/A
TerminatedCPAP Improving Mortality for Pneumonia in African Children Trial
NCT02484183
Johns Hopkins UniversityN/A
CompletedComparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficie
NCT02403674
Merck Sharp & Dohme LLCPhase 3
CompletedRegular HIV Testing Among At-Risk Latino Men
NCT02454725
Medical College of WisconsinN/A
CompletedA Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infe
NCT02388594
University of PennsylvaniaPhase 1
CompletedPericardial Fat and Inflammation in HIV Patients and Controls
NCT02399384
University of Cincinnati
CompletedPhase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophyl
NCT02165202
PATHPhase 2
CompletedThe Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients
NCT02234492
Ottawa Heart Institute Research CorporationPhase 4
CompletedRepeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
NCT02225665
Sangamo TherapeuticsPhase 1 / Phase 2
CompletedIntervention to Enhance PrEP Uptake and Adherence in a Community-Based Setting
NCT02037594
Hunter College of City University of New YorkN/A
CompletedEnhanced HIV Prevention in Couples: Feasibility Study #3
NCT02027519
Columbia University
UnknownAssessment of Group Peer Support to Children With HIV in Vietnam
NCT02035969
Karolinska InstitutetN/A
CompletedShedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected
NCT02474901
University of Colorado, DenverPhase 2
CompletedEvaluating Rewards-Based Adherence and Electronic Medication Monitoring in HIV-Positive Adolescents
NCT01849393
St. Jude Children's Research Hospital
CompletedEnhanced Prevention in Couples: Feasibility Study #2
NCT02027441
Columbia University
CompletedImmunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults
NCT01685372
University of Colorado, DenverPhase 2
CompletedMulti-level Determinants of Starting ART Late: Aim 3
NCT01997359
Columbia University
CompletedPediatric Enhanced Surveillance Study
NCT02043769
Columbia University
No Longer AvailableCompassionate Use of Ibalizumab for the Treatment of HIV Infection
NCT02028819
University of Colorado, Denver
CompletedAn Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART
NCT01541085
Janssen-Cilag S.p.A.
CompletedHuman Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
NCT01516970
Janssen-Cilag G.m.b.HPhase 3
CompletedMulti-level Determinants of Starting ART Late: Aim 2
NCT01997346
Columbia University
CompletedAn Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients
NCT01615601
Janssen Inc.
CompletedA Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)
NCT01449006
Bruce BrewPhase 4
TerminatedA Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV
NCT01448486
St Vincent's Hospital, SydneyPhase 4
CompletedSteering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men
NCT02572401
University of PennsylvaniaN/A
CompletedFeasibility of a Stigma Reduction Intervention for Human Immunodeficiency Virus (HIV)-Infected Women
NCT01385241
Duke UniversityN/A
CompletedEnhanced HIV Prevention in Couples: Feasibility Study #1
NCT02027714
Columbia University
CompletedThe Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System
NCT01206933
George Washington University
UnknownDiagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/
NCT01875952
Instituto Nacional de Salud Publica, MexicoPhase 4
CompletedA Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment
NCT01199939
Tibotec, IncPhase 2
CompletedStudy of Vitamin D and Effect on Heart Disease and Insulin Resistance
NCT01093417
University Hospitals Cleveland Medical CenterPhase 2
CompletedA Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Com
NCT01045317
PfizerPhase 1
CompletedImpact of Nutrition Intervention on HIV/AIDS Infected Patients
NCT01171495
Caribbean Health Research CouncilPhase 3
CompletedEffect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission
NCT01053741
Johns Hopkins UniversityN/A
UnknownAntiretroviral Treatment Strategies in Relation to Adherence, Resistance and Virological Treatment Failure
NCT01433601
Karolinska InstitutetN/A
CompletedALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens
NCT00335322
Kirby InstitutePhase 4
CompletedSPL7013 Gel - Male Tolerance Study
NCT00370357
Starpharma Pty LtdPhase 1
CompletedA Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immun
NCT03407105
Bristol-Myers SquibbPhase 1
No Longer AvailableA Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Com
NCT00992654
ViiV Healthcare